Results 71 to 80 of about 7,642 (118)

2018—2022年苏州地区血流感染患儿病原菌分布和耐药性分析 附视频

Zhongguo shiyan zhenduanxue
目的 探讨苏州地区住院患儿血流感染病原菌的分布和耐药特征，为该类患者的血流感染诊治提供依据。方法 回顾性分析2018年1月至2022年12月南京医科大学附属苏州医院血培养阳性患儿的临床资料、病原菌分布及其对抗菌药物的耐药情况。结果 896例血培养阳性患儿中，新生儿719例(占80.2%),非新生儿177例(占19.8%)。在分离出的926株病原菌中，以革兰阳性菌为主(65.9%),革兰阴性菌占33.4%,真菌仅占0.8%。最常见的病原菌为表皮葡萄球菌(32.6%),其次是头状葡萄球菌 ...
doaj   +2 more sources

[Ethanol promotes oxaliplatin resistance in colorectal cancer by activating the TGF‑β/Smad/P21 signaling axis]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Tan B, Weng N, Zeng W, Gu J, Weng L, Wen H, Xiao H, Zheng K.   +7 more
europepmc   +1 more source

2 643株腹腔感染病原菌分布及耐药性分析

Zhongguo shiyan zhenduanxue
目的分析吉林大学中日联谊医院由腹腔感染病例中分离出的病原菌分布及耐药性特征，为经验性抗感染治疗和本地化细菌耐药监测提供依据。方法回顾性收集2023年1月1日至2025年9月30日期间，吉林大学中日联谊医院各科室腹腔感染患者的病原学资料。采用VITEK MS进行病原菌鉴定，Vitek 2 Compact、纸片扩散法及E-test进行药物敏感性试验，按CLSI 2021标准判读。利用WHONET 5.6对病原菌构成及耐药性进行统计与分析。结果病原菌总计2 643株，其中男性占比65.7%，年龄> ...
王思博, 鄢超, 宋丽娜, 刘豪, 姜钧天, 焦美玲, 徐雪松   +6 more
doaj  

[Distribution and Drug Resistance Characteristics of Pathogenic Bacteria in the Elderly Population in China in 2021]. [PDF]

Sichuan Da Xue Xue Bao Yi Xue Ban
Tang S, Xiao Y, Li J, Li D, Wu S, Huang X, Li J, Yang L, Li J, Wang T, Zhang G, Xu Y, Xie Y.   +12 more
europepmc   +1 more source

A single-center retrospective study of pathogen distribution and antibiotic resistance of bloodstream infections in emergency department. [PDF]

Zhong Nan Da Xue Xue Bao Yi Xue Ban
Tang Y, Chen L, Xiao J, Yan K, Qi J, Zhou K, Liu H.   +6 more
europepmc   +1 more source

[Application of Nano-drug Delivery Technology in Overcoming Drug Resistance 
in Lung Cancer]. [PDF]

Zhongguo Fei Ai Za Zhi
Lu Y, Wang C, Liu B.
europepmc   +1 more source

[Distribution of the Pathogens Isolated from 6428 Tumor Patients in 2019-2023 and the Relevant Drug Resistance Surveillance Report]. [PDF]

Sichuan Da Xue Xue Bao Yi Xue Ban
Tang Q, Wang Y, Yuan Y, Shu L, Deng J, He C.   +5 more
europepmc   +1 more source

免疫检查点抑制剂耐药机制研究进展

Zhongshan Daxue xuebao. Yixue kexue ban
免疫检查点抑制剂（ICIs）通过解除对免疫系统的抑制性调控机制，恢复并增强机体的抗肿瘤免疫应答，为肿瘤治疗带来里程碑式飞跃，彻底改变了多种恶性肿瘤的治疗模式，使部分患者的生存期显著延长。然而，临床实践中发现多数患者对ICIs治疗产生原发性耐药（初始治疗无应答）或获得性耐药（疾病得到控制后出现的耐药），极大地限制了其在临床上的广泛应用。ICIs耐药表型的产生可能源于不同的生物学机制，耐药机制复杂，涉及肿瘤细胞自身特性改变、肿瘤微环境重塑以及机体免疫系统状态等多个层面。深入探究ICIs耐药机制 ...
杨彩波, 符立梧
doaj  

[Chinese expert consensus on the diagnosis and treatment strategies for refractory/resistant cytomegalovirus infection in immunocompromised populations (2025)]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Infectiology Group, Chinese Society of Hematology, Chinese Medical Association, Chinese Society of Organ Transplantation, Chinese Society of Clinical Oncology Leukemia Expert Committee, Guangdong Medical Association of Respiratory Medicine, Guangdong Association of Primary Medicine Immunodeficiency Committee.   +6 more
europepmc   +1 more source

[METTL3-mediated m⁶A modification promotes FOXO3 expression and anthracycline resistance in acute myeloid leukemia cells through autophagy regulation]. [PDF]

Nan Fang Yi Ke Da Xue Xue Bao
Zhang X, Yang J, Wen Y, Liu Q, Dou L, Gao C.   +5 more
europepmc   +1 more source